The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
The Immune Revolution: A Case for Priming, Not Checkpoint
Open accessAbstract
Most tumors are unresponsive to immune checkpoint blockade, especially if deep immunosuppression in the tumor develops prior to and prevents T cell immunosurveillance. Failed or frustrated T-cell priming often needs repair before successful sensitization to PD-1/PD-L1 blockade. CD40 activation plays a critical role in generating T cell immunity, by activating dendritic cells, and converting cold tumors to hot. In preclinical studies, agonistic CD40 antibodies demonstrate T cell-dependent anti-tumor activity, especially in combination with chemotherapy, checkpoint inhibitory antibodies, and other immune modulators. With the advent of multiple CD40 agonists with acceptable single-agent toxicity, clinical evaluation of CD40 combinations has accelerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 2×
“In humans, T cell exclusion in PDA – with marked surrounding desmoplasia – is also well-described; however, a subset of primary pancreatic tumors do exhibit moderate infiltration of CD8+ T cells and other immune cells (Bailey et al., 2016; Balachandran et al., 2017; Fukunaga et al., 2004; Ino et al., 2013b; Wormann et…”
BackgroundIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
Albert, M. L., Sauter, B., & Bhardwaj, N. (1998) · Nature · doi:10.1038/32183 · Cited by 2,349
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Self-citationCasanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
van Kooten, C., & Banchereau, J. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.2 · Cited by 1,404
DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,353
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,201
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,026
Mechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
Self-citationCross-Presentation, Dendritic Cells, Tolerance and Immunity
Heath, W. R., & Carbone, F. R. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.47 · Cited by 882
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. (2004) · Pancreas · doi:10.1097/00006676-200401000-00023 · Cited by 532
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3311 · Cited by 513
Self-citationBruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
Sánchez-Paulete, A. R., Cueto, F. J., Martínez-López, M., Labiano, S., Morales-Kastresana, A., Rodríguez-Ruiz, M. E., Jure-Kunkel, M., Azpilikueta, A., Aznar, M. A., Quetglas, J. I., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0510 · Cited by 484
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459
Self-citationBeatty, G. L., Torigian, D. A., Chiorean, E. G., Saboury, B., Brothers, A., Alavi, A., Troxel, A. B., Sun, W., Teitelbaum, U. R., Vonderheide, R. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1320 · Cited by 456
Self-citationSynergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 421
Agonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414
Self-citationFunctions of Murine Dendritic Cells
Durai, V., & Murphy, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.010 · Cited by 413
Duan, F., Duitama, J., Al Seesi, S., Ayres, C. M., Corcelli, S. A., Pawashe, A. P., Blanchard, T., McMahon, D., Sidney, J., Sette, A., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141308 · Cited by 378
Ahonen, C. L., Doxsee, C. L., McGurran, S. M., Riter, T. R., Wade, W. F., Barth, R. J., Vasilakos, J. P., Noelle, R. J., & Kedl, R. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031591 · Cited by 362
Lanzavecchia, A. (1998) · Nature · doi:10.1038/30845 · Cited by 360
Schultze, J. L., Michalak, S., Seamon, M. J., Dranoff, G., Jung, K., Daley, J., Delgado, J. C., Gribben, J. G., & Nadler, L. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119822 · Cited by 355
Li, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Aspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E. C., Su, D., Marches, F., Banchereau, J., & Palucka, A. K. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061120 · Cited by 334
Engelhardt, J. J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., & Krummel, M. F. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.008 · Cited by 330
Beatty, G. L., Winograd, R., Evans, R. A., Long, K. B., Luque, S. L., Lee, J. W., Clendenin, C., Gladney, W. L., Knoblock, D. M., Guirnalda, P. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.010 · Cited by 293
Self-citationCD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282 · cited 18×
“However, the addition of nab-paclitaxel (nP) to gemcitabine, which is a combination more effective in patients than Gem alone, synergizes to trigger tumor regression, establish T cell memory, and improve survival in subcutaneous, orthotopic, and spontaneous KPC tumors (Byrne and Vonderheide, 2016).”
BackgroundInfluentialSelf-citationVerbrugge, I., Hagekyriakou, J., Sharp, L. L., Galli, M., West, A., McLaughlin, N. M., Duret, H., Yagita, H., Johnstone, R. W., Smyth, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0210 · Cited by 275
Eradication of established tumors in mice by a combination antibody-based therapy
Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F., Okumura, K., Yagita, H., & Smyth, M. J. (2006) · Nature Medicine · doi:10.1038/nm1405 · Cited by 257
Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
Balli, D., Rech, A. J., Stanger, B. Z., & Vonderheide, R. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2128 · Cited by 235
Self-citationInteraction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
White, A. L., Chan, H. T. C., Roghanian, A., French, R. R., Mockridge, C. I., Tutt, A. L., Dixon, S. V., Ajona, D., Verbeek, J. S., Al-Shamkhani, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101135 · Cited by 226
Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients
Vonderheide, R. H., Dutcher, J. P., Anderson, J. E., Eckhardt, S. G., Stephans, K. F., Razvillas, B., Garl, S., Butine, M. D., Perry, V. P., Armitage, R. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3280 · Cited by 223
Self-citationvan Mierlo, G. J. D., den Boer, A. T., Medema, J. P., van der Voort, E. I. H., Fransen, M. F., Offringa, R., Melief, C. J. M., & Toes, R. E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082107699 · Cited by 222
The immune network in pancreatic cancer development and progression
Wörmann, S. M., Diakopoulos, K. N., Lesina, M., & Algül, H. (2014) · Oncogene · doi:10.1038/onc.2013.257 · Cited by 205
Vonderheide, R. H., Burg, J. M., Mick, R., Trosko, J. A., Li, D., Shaik, M. N., Tolcher, A. W., & Hamid, O. (2013) · OncoImmunology · doi:10.4161/onci.23033 · Cited by 202
Self-citationStromnes, I. M., Schmitt, T. M., Hulbert, A., Brockenbrough, J. S., Nguyen, H. N., Cuevas, C., Dotson, A. M., Tan, X., Hotes, J. L., Greenberg, P. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.022 · Cited by 200
Inflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 200
Self-citationProspect of Targeting the CD40 Pathway for Cancer Therapy
Vonderheide, R. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1893 · Cited by 186
Self-citationBroz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.010 · Cited by 182
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen
Evans, R. A., Diamond, M. S., Rech, A. J., Chao, T., Richardson, M. W., Lin, J. H., Bajor, D. L., Byrne, K. T., Stanger, B. Z., Riley, J. L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88328 · Cited by 180
Self-citationWhite, A. L., Chan, H. T. C., French, R. R., Willoughby, J., Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G., Dodhy, A., Polak, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.001 · Cited by 173
Dahan, R., Barnhart, B. C., Li, F., Yamniuk, A. P., Korman, A. J., & Ravetch, J. V. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.001 · Cited by 165
Ino, Y., Yamazaki–Itoh, R., Oguro, S., Shimada, K., Kosuge, T., Závada, J., Kanai, Y., & Hiraoka, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055146 · Cited by 160
Rüter, J., Antonia, S. J., Burris, H. A., Huhn, R. D., & Vonderheide, R. H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13251 · Cited by 155
Self-citationInduced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Zippelius, A., Schreiner, J., Herzig, P., & Müller, P. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0226 · Cited by 145
Metastatic progression is associated with dynamic changes in the local microenvironment
Aiello, N. M., Bajor, D. L., Norgard, R. J., Sahmoud, A., Bhagwat, N., Pham, M. N., Cornish, T. C., Iacobuzio–Donahue, C. A., Vonderheide, R. H., & Stanger, B. Z. (2016) · Nature Communications · doi:10.1038/ncomms12819 · Cited by 144
Self-citationCoughlin, C. M., Vance, B. A., Grupp, S. A., & Vonderheide, R. H. (2003) · Blood · doi:10.1182/blood-2003-07-2379 · Cited by 140
Self-citationScarlett, U. K., Cubillos‐Ruiz, J. R., Nesbeth, Y. C., Martinez, D. G., Engle, X. A., Gewirtz, A. T., Ahonen, C. L., & Conejo-Garcia, J. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0835 · Cited by 137
Grewal, I. S., & Flavell, R. A. (1997) · Immunologic Research · doi:10.1007/bf02786323 · Cited by 131
Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
Johnson, P., Challis, R., Chowdhury, F., Gao, Y., Harvey, M., Geldart, T., Kerr, P., Chan, H. T. C., Smith, A., Steven, N. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2355 · Cited by 118
Awakening the immune system with radiation: Optimal dose and fractionation
Gandhi, S. J., Minn, A. J., Vonderheide, R. H., Wherry, E. J., Hahn, S. M., & Maity, A. M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.024 · Cited by 112
Self-citationChemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system
Ciampricotti, M., Hau, C., Doornebal, C. W., Jonkers, J., & de Visser, K. E. (2012) · Nature Medicine · doi:10.1038/nm.2652 · Cited by 108
Poschke, I. C., Faryna, M., Bergmann, F., Floßdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T. P., Ehrenberg, R., Volkmar, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240859 · Cited by 106
Nowak, A. K., Cook, A., McDonnell, A. M., Millward, M., Creaney, J., Francis, R. J., Hasani, A., Segal, A., Musk, A. W., Turlach, B. A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv387 · Cited by 104
Sandin, L. C., Orlova, A., Gustafsson, E., Ellmark, P., Максимилианович, Т. В., Tötterman, T. H., & Mangsbo, S. M. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0067 · Cited by 101
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor
Ngiow, S. F., Young, A., Blake, S. J., Hill, G. R., Yagita∥, H., Teng, M. W. L., Korman, A. J., & Smyth, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2141 · Cited by 95
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
Rech, A. J., Balli, D., Mantero, A. M. A., Ishwaran, H., Nathanson, K. L., Stanger, B. Z., & Vonderheide, R. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0559 · Cited by 95
Self-citationBroomfield, S., der Most, R. G. V., Prosser, A., Mahendran, S., Tovey, M. G., Smyth, M. J., Robinson, B. W. S., & Currie, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803826 · Cited by 93
Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
Richman, L. P., & Vonderheide, R. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0152 · Cited by 92
Self-citationAhonen, C. L., Wasiuk, A., Fuse, S., Turk, M. J., Ernstoff, M. S., Suriawinata, A. A., Gorham, J. D., Kedl, R. M., Usherwood, E. J., & Noelle, R. J. (2008) · Blood · doi:10.1182/blood-2007-09-114371 · Cited by 86
Carpenter, E. L., Mick, R., Rüter, J., & Vonderheide, R. H. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-93 · Cited by 75
Self-citationFcγRΙΙB controls the potency of agonistic anti-TNFR mAbs
White, A. L., Chan, H. T. C., French, R. R., Beers, S. A., Cragg, M. S., Johnson, P., & Glennie, M. J. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1398-6 · Cited by 43
Bajor, D. L., Xu, X., Torigian, D. A., Mick, R., Garcia, L. R., Richman, L. P., Desmarais, C., Nathanson, K. L., Schuchter, L. M., Kalos, M. D., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0154 · Cited by 43
Self-citationPriming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy
Lutz, E. R., Kinkead, H. L., Jaffee, E. M., & Zheng, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.962401 · Cited by 40
Bajor, D. L., Mick, R., Riese, M. J., Richman, L. P., Xu, X., Torigian, D. A., Stelekati, E., Sweeney, M., Sullivan, B. J., Schuchter, L. M., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ct137 · Cited by 27
Self-citationDevelopment of metastatic HER2+ breast cancer is independent of the adaptive immune system
Ciampricotti, M., Vrijland, K., Hau, C., Pemovska, T., Doornebal, C. W., Speksnijder, E. N., Wartha, K., Jonkers, J., & de Visser, K. E. (2010) · The Journal of Pathology · doi:10.1002/path.2837 · Cited by 26
The Use of Anti-CD40 mAb in Cancer
Remer, M., White, A. L., Glennie, M. J., Al‐Shamkhani, A., & Johnson, P. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_427 · Cited by 23
CD154 Gene Therapy for Human B‐Cell Malignancies
Messmer, D., & Kipps, T. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1358.008 · Cited by 18
McDonnell, A. M., Cook, A., Robinson, B. W. S., Lake, R., & Nowak, A. K. (2017) · BMC Cancer · doi:10.1186/s12885-017-3403-5 · Cited by 12
Cited by
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Metadata
- Authors
- Vonderheide, R. H.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 33
- Issue
- 4
- Pages
- 563-569
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2796894486
- Cited by
- 293
- References
- 91
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.